Research programme: obesity therapy - AdipoGenix/CombinatoRx
Latest Information Update: 14 Aug 2009
Price :
$50 *
At a glance
- Originator AdipoGenix; CombinatoRx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 14 Aug 2009 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 16 May 2006 Preclinical trials in Obesity in USA (unspecified route)